The Human Mucosal Immune Responses to Influenza Virus (SLVP026)
The Human Mucosal Immune Responses to Influenza Virus: A Systems Biology Approach. Innate Immune Responses to Influenza Virus in Single Human Nasal Epithelial Cells
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
This PHASE4 trial investigates Influenza and is currently completed. National Institute of Allergy and Infectious Diseases (NIAID) leads this study, which shows 8 recorded versions since 2012 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE4
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE4
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE4
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE4
-
May 2017 — Jun 2018 [monthly]
Completed PHASE4
-
Feb 2017 — May 2017 [monthly]
Completed PHASE4
First recorded
Dec 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Institute of Allergy and Infectious Diseases (NIAID)
- Stanford University
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.